Investment Analysts’ Recent Ratings Updates for Versartis (VSAR)

Versartis (NASDAQ: VSAR) has recently received a number of price target changes and ratings updates:

  • 8/2/2017 – Versartis was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/2/2017 – Versartis was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California. “
  • 7/28/2017 – Versartis was given a new $28.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/27/2017 – Versartis was given a new $34.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/24/2017 – Versartis was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/16/2017 – Versartis was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/29/2017 – Versartis was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California. “
  • 6/27/2017 – Versartis was given a new $26.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.

Versartis, Inc. (NASDAQ:VSAR) traded up 0.85% during midday trading on Thursday, reaching $17.70. 179,920 shares of the company traded hands. The stock’s 50 day moving average is $17.66 and its 200 day moving average is $17.90. The company’s market capitalization is $623.20 million. Versartis, Inc. has a one year low of $9.05 and a one year high of $24.00.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.20. On average, equities analysts anticipate that Versartis, Inc. will post ($3.15) earnings per share for the current year.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Receive News & Ratings for Versartis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply